IL212277A0 - Compositions for use in treating thymic stromal lymphopoietin (tslp)-mediated conditions - Google Patents

Compositions for use in treating thymic stromal lymphopoietin (tslp)-mediated conditions

Info

Publication number
IL212277A0
IL212277A0 IL212277A IL21227711A IL212277A0 IL 212277 A0 IL212277 A0 IL 212277A0 IL 212277 A IL212277 A IL 212277A IL 21227711 A IL21227711 A IL 21227711A IL 212277 A0 IL212277 A0 IL 212277A0
Authority
IL
Israel
Prior art keywords
tslp
compositions
mediated conditions
thymic stromal
stromal lymphopoietin
Prior art date
Application number
IL212277A
Original Assignee
Revalesio Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/258,210 external-priority patent/US20090274730A1/en
Application filed by Revalesio Corp filed Critical Revalesio Corp
Publication of IL212277A0 publication Critical patent/IL212277A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Otolaryngology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
IL212277A 2008-10-22 2011-04-12 Compositions for use in treating thymic stromal lymphopoietin (tslp)-mediated conditions IL212277A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10748008P 2008-10-22 2008-10-22
US10745308P 2008-10-22 2008-10-22
US12/258,210 US20090274730A1 (en) 2007-10-25 2008-10-24 Compositions and methods for treating inflammation
PCT/US2009/061710 WO2010048425A1 (en) 2008-10-22 2009-10-22 Compositions and methods for treating thymic stromal lymphopoietin (tslp)-mediated conditions

Publications (1)

Publication Number Publication Date
IL212277A0 true IL212277A0 (en) 2011-06-30

Family

ID=42119683

Family Applications (2)

Application Number Title Priority Date Filing Date
IL212277A IL212277A0 (en) 2008-10-22 2011-04-12 Compositions for use in treating thymic stromal lymphopoietin (tslp)-mediated conditions
IL212309A IL212309A (en) 2008-10-22 2011-04-13 Compositions for use in treating matrix metalloproteinase 9 (mmp9)-mediated conditions

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL212309A IL212309A (en) 2008-10-22 2011-04-13 Compositions for use in treating matrix metalloproteinase 9 (mmp9)-mediated conditions

Country Status (9)

Country Link
EP (2) EP2350263A4 (en)
JP (4) JP5688370B2 (en)
CN (2) CN102256607B (en)
AU (2) AU2009308362B2 (en)
BR (2) BRPI0920201A2 (en)
CA (2) CA2741341A1 (en)
IL (2) IL212277A0 (en)
MX (2) MX337035B (en)
WO (2) WO2010048425A1 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6702949B2 (en) 1997-10-24 2004-03-09 Microdiffusion, Inc. Diffuser/emulsifier for aquaculture applications
US8445546B2 (en) 2006-10-25 2013-05-21 Revalesio Corporation Electrokinetically-altered fluids comprising charge-stabilized gas-containing nanostructures
EP2086668B1 (en) 2006-10-25 2016-11-16 Revalesio Corporation Mixing device and method
WO2008052145A2 (en) 2006-10-25 2008-05-02 Revalesio Corporation Methods of therapeutic treatment of eyes and other human tissues using an oxygen-enriched solution
US9523090B2 (en) 2007-10-25 2016-12-20 Revalesio Corporation Compositions and methods for treating inflammation
US9745567B2 (en) 2008-04-28 2017-08-29 Revalesio Corporation Compositions and methods for treating multiple sclerosis
US10125359B2 (en) 2007-10-25 2018-11-13 Revalesio Corporation Compositions and methods for treating inflammation
CN102076326B (en) * 2008-04-28 2015-12-02 利发利希奥公司 The compositions for the treatment of multiple sclerosis and method
JP5901291B2 (en) 2008-05-01 2016-04-06 リバルシオ コーポレイション Compositions and methods for treating digestive disorders
US8815292B2 (en) 2009-04-27 2014-08-26 Revalesio Corporation Compositions and methods for treating insulin resistance and diabetes mellitus
AU2011249856B2 (en) 2010-05-07 2015-11-26 Revalesio Corporation Compositions and methods for enhancing physiological performance and recovery time
EP2603202A4 (en) 2010-08-12 2016-06-01 Revalesio Corp Compositions and methods for treatment of taupathy
CN103561722A (en) * 2011-04-13 2014-02-05 利发利希奥公司 Compositions and methods for inhibiting and/or modulating effector t-cells involved in inflammatory neurodegenerative disease
CN102268069B (en) * 2011-07-01 2012-11-28 中国药科大学 Substrate metal prolease-9 polypeptide inhibitor 4 and application thereof
CN102250213B (en) * 2011-07-01 2012-11-07 中国药科大学 Matrix metalloproteinase-9 polypeptide inhibitor 3 and application thereof
CN102268070B (en) * 2011-07-01 2012-11-28 中国药科大学 Substrate metal prolease-9 polypeptide inhibitor 2 and application thereof
KR101492435B1 (en) * 2012-12-28 2015-02-10 고려대학교 산학협력단 COMPOSITION FOR PREVENTING OR TREATING TSLP-MEDIATED DISEASES COMPRISING siRNA AGAINST HIF-1α AS AN ESSENTIAL COMPONENT
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
CN105477628B (en) * 2014-09-19 2021-04-30 山东蓝金生物工程有限公司 Anticancer composition and use thereof
CN106943593A (en) * 2017-03-24 2017-07-14 浙江中医药大学 Application of the anti-TSLP antibody in the chronic itch medicine of preventing and treating is prepared
US11345758B2 (en) 2017-06-27 2022-05-31 Translational Sciences, Inc. Inhibition of vascular matrix metalloproteinase-9 to treat ischemic injury
US20220233641A1 (en) * 2019-05-17 2022-07-28 The Trustees Of The University Of Pennsylvania Methods and Compositions for Treating Obesity and/or Skin Disorders
CN112876564B (en) * 2019-11-29 2022-07-15 康诺亚生物医药科技（成都）有限公司 Development and application of TSLP (TSLP-related disease treatment agent)

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2289817T3 (en) * 1998-07-28 2008-02-01 The Regents Of The University Of California NUCLEIC ACIDS CODING A RECEPTOR COUPLED TO PROTEINS AND INVOLVED IN SENSORY TRANSDUCTION.
CN101850120A (en) * 1999-07-21 2010-10-06 奥默罗斯公司 Be used for inhibition of pain, the solution of inflammation and cartilage degradation and method
US20040235732A1 (en) * 2000-11-03 2004-11-25 Qun-Yong Zhou Method for modulating angiogenesis using prokineticin receptor antagonists
US20030232114A1 (en) * 2002-06-13 2003-12-18 Nikola Dekleva Method for liquid enrichment with oxygen and applications of enriched liquids
AU2002321678A1 (en) * 2002-09-09 2004-03-29 Boros Béla Oxygen-enriched water, treated within a magnetic field and heavy water
US20070077553A1 (en) * 2003-10-30 2007-04-05 Rosetta Genomics Bioinformatically detectable group of novel vaccinia regulatory genes and uses thereof
EP1599165A4 (en) * 2003-02-10 2010-09-08 Univ Jefferson The use of gcc ligands
US20090010920A1 (en) * 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US7393924B2 (en) * 2004-01-06 2008-07-01 Franco Vitaliano Smart bio-nanoparticle elements
KR100583430B1 (en) * 2004-03-08 2006-05-24 양경숙 Wheel-exchangeable scooter
US20050249712A1 (en) * 2004-03-23 2005-11-10 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Methods for use of TSLP and agonists and antagonists thereof
WO2008018932A2 (en) * 2006-05-01 2008-02-14 The Board Of Trustees Of The Leland Stanford Junior University Method and use of nano-scale devices for reduction of tissue injury in ischemic and reperfusion injury
US20080050452A1 (en) * 2006-06-30 2008-02-28 Nucryst Pharmaceuticals Metal-containing formulations and methods of use
WO2008052145A2 (en) * 2006-10-25 2008-05-02 Revalesio Corporation Methods of therapeutic treatment of eyes and other human tissues using an oxygen-enriched solution
EP2086668B1 (en) * 2006-10-25 2016-11-16 Revalesio Corporation Mixing device and method
CA2667614A1 (en) * 2006-10-25 2008-09-25 Revalesio Corporation Method of wound care and treatment
MX2010004563A (en) * 2007-10-25 2010-07-28 Revalesio Corp Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction.
CN102076326B (en) * 2008-04-28 2015-12-02 利发利希奥公司 The compositions for the treatment of multiple sclerosis and method

Also Published As

Publication number Publication date
MX337035B (en) 2016-02-09
JP5688371B2 (en) 2015-03-25
AU2009308302A1 (en) 2010-04-29
EP2350263A4 (en) 2013-07-03
AU2009308302B2 (en) 2016-01-21
JP2012506451A (en) 2012-03-15
MX2011004233A (en) 2011-06-24
JP5688370B2 (en) 2015-03-25
AU2009308362B2 (en) 2016-02-04
MX2011004235A (en) 2011-06-24
BRPI0920201A2 (en) 2019-09-10
CN102257130B (en) 2016-07-06
CN102256607B (en) 2014-11-05
CA2741341A1 (en) 2010-04-29
EP2364154A1 (en) 2011-09-14
JP2015044868A (en) 2015-03-12
WO2010048455A1 (en) 2010-04-29
JP2015044869A (en) 2015-03-12
IL212309A0 (en) 2011-06-30
JP2012506453A (en) 2012-03-15
EP2364154A4 (en) 2013-07-10
EP2350263A1 (en) 2011-08-03
WO2010048425A1 (en) 2010-04-29
CN102257130A (en) 2011-11-23
BRPI0920430A2 (en) 2019-09-24
CA2741336A1 (en) 2010-04-29
AU2009308362A1 (en) 2010-04-29
IL212309A (en) 2016-04-21
CN102256607A (en) 2011-11-23

Similar Documents

Publication Publication Date Title
IL212277A0 (en) Compositions for use in treating thymic stromal lymphopoietin (tslp)-mediated conditions
HRP20190214T1 (en) Compositions and methods for treating purpura
HK1200485A1 (en) Methods and compositions for facilitating regeneration
ZA201006944B (en) Compositions and methods for preparing and using same
GB2476624B (en) Compositions and methods for tissue repair with extracellular matrices
IL210153A0 (en) Nutrigenomics methods and compositions
EP2148569A4 (en) Methods and compositions for stem cell self-renewal
IL219827A0 (en) Lyophilization methods, compositions, and kits
IL212822A0 (en) Anti-cxcr1 compositions and methods
GB0819530D0 (en) Methods and compositions
IL210559A0 (en) Novel compositions and methods
IL210588A0 (en) Novel compositions and methods
EP2294199A4 (en) Compositions and methods for improving plants
EP2424978A4 (en) Compositions and methods for modulating stem cells and uses thereof
EP2294198A4 (en) Methods and compositions for plant improvement
GB0811250D0 (en) Methods and compositions
EP2516649A4 (en) Novel pneumovirus compositions and methods for using the same
IL207113A0 (en) Erythropietin and fibronectin compositions for bone regeneration
GB0811152D0 (en) Methods and compositions
GB0818399D0 (en) Methods and compositions